Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 0.84 |
| ▸ | PARP1 | P09874 | 4/20 | 0.80 |
| ▸ | HTR1D | P28221 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906052 | 0.92 | DRD4 (1.00) | DRD4DRD2DRD3PARP1 | |
| SCHEMBL532657 | 0.90 | DRD2 (0.81) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL6910538 | 0.90 | DRD4 (1.00) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL2122618 | 0.89 | DRD4 (0.81) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL532442 | 0.89 | PARP1 (1.00) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL6907258 | 0.89 | DRD4 (1.00) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL6908421 | 0.83 | DRD4 (1.00) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL532095 | 0.82 | PARP1 (0.83) | DRD4DRD2DRD3PARP1 | |
| SCHEMBL532493 | 0.81 | PARP1 (1.00) | DRD4DRD2DRD3PARP1HTR1D | |
| SCHEMBL6967713 | 0.81 | DRD4 (1.00) | DRD4DRD2DRD3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906294-B1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2003-01-29 | — | — | EP | claimed |
| US-6177422-B1 | ANTIPSYCHOTIC AGENT WITH REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY | 2001-01-23 | — | — | US | claimed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| EP-0906294-B1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | disclosed |
| US-6177422-B1 | ANTIPSYCHOTIC AGENT WITH REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY | 2001-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885DRD3 31/4885 |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | DRD4 31/4885DRD2 35/4885DRD3 55/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885DRD3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.